Integra LifeSciences updated presentation materials for use with existing and prospective lenders as it plans to refinance its outstanding senior Credit Facility in 2026. The materials matter to investors because they outline the information the company intends to present during refinancing discussions, while limiting distribution to qualified institutional buyers and non-U.S. persons.

Key Highlights

  • The presentation is available only to qualified institutional buyers and non-U.S. Persons.
  • Integra describes Specialty Surgery and Tissue Reconstruction as its two operating segments.
  • The materials include non-GAAP measures such as adjusted EBITDA, free Cash Flow and net debt.

Integra LifeSciences Holdings Corp (NASDAQ: IART) has updated its investor presentation for discussions with existing and prospective lenders tied to refinancing its outstanding senior credit facility in 2026. The materials may be used periodically during those lender presentations.

Updated Materials Outline Refinancing Plans

The presentation is dated September 8, 2026, and is restricted to qualified institutional buyers and non-U.S. Persons. Integra describes its Business through Specialty Surgery and Tissue Reconstruction. The materials state that 2026 is a key inflection period as Integra progresses through FDA-mandated Manufacturing and quality-system remediation. They also include forward-looking statements concerning operational and financial performance, strategic initiatives, manufacturing, product development, regulatory approvals and quality-system compliance. The presentation identifies risks including geopolitical tension, trade restrictions, supply-chain disruption, interest-rate and foreign-currency fluctuations, regulatory delays, manufacturing interruptions, competition, reimbursement decisions and the company’s assessment of flooding at its Cincinnati, Ohio, manufacturing facility. Integra also defines non-GAAP measures including organic revenues, adjusted EBITDA, adjusted gross profit, free cash flow and net debt.